Keeping up with the clinical advances: tardive dyskinesia

被引：2

作者：

Elkurd, Mazen T. ^{[1
]}

Bahroo, Laxman ^{[1
]}

机构：

[1] Medstar Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA

来源：

CNS SPECTRUMS | 2019年 / 24卷

关键词：

Tardive dyskinesia; clinical advances; TD; DRBA; Parkinsonism; DOUBLE-BLIND; CONTROLLED-TRIAL; TETRABENAZINE; LEVETIRACETAM; VITAMIN-B-6; AMANTADINE; DEUTETRABENAZINE; METAANALYSIS; PROPRANOLOL; IMPROVEMENT;

D O I：

10.1017/S1092852919001263

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Tardive dyskinesia (TD) was first described in 1964, but treatment for this sometimes poorly characterized condition lagged decades as it was labored by medico-legal implications. TD has often been lumped with other medication-induced disorders and incorrectly classified as extrapyramidal symptoms. TD is likely to be under-recognized for many of these reasons. Though diverse in its presentations, TD is distinct in terms of time course, pathophysiology, and phenomenology.

引用

页码：73 / 80

页数：8

共 50 条

[1] Recent Advances in the Pharmacology of Tardive Dyskinesia
Caroff, Stanley N.
[J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2020, 18 (04) : 493 - 506
[2] Keeping up with the clinical advances: depression
Ragguett, Renee-Marie
Tamura, Jocelyn K.
McIntyre, Roger S.
[J]. CNS SPECTRUMS, 2019, 24 : 28 - 36
[3] Clinical implications of pharmacogenomics for tardive dyskinesia
Müller, DJ
Shinkai, T
De Luca, V
Kennedy, JL
[J]. PHARMACOGENOMICS JOURNAL, 2004, 4 (02): : 77 - 87
[4] CLINICAL FACTORS IN TARDIVE-DYSKINESIA
STRAKER, M
[J]. PSYCHIATRIC JOURNAL OF THE UNIVERSITY OF OTTAWA-REVUE DE PSYCHIATRIE DE L UNIVERSITE D OTTAWA, 1980, 5 (01): : 28 - 33
[5] Clinical implications of pharmacogenomics for tardive dyskinesia
D J Müller
T Shinkai
V De Luca
J L Kennedy
[J]. The Pharmacogenomics Journal, 2004, 4 : 77 - 87
[6] TARDIVE DYSKINESIA: CLINICAL PRESENTATION AND TREATMENT
van Harten, Peter N.
Tenback, Diederik E.
[J]. PATHOPHYSIOLOGY, PHARMACOLOGY, AND BIOCHEMISTRY OF DYSKINESIA, 2011, 98 : 187 - 210
[7] Clinical characteristics of patients with tardive dyskinesia
Held, T
Weber, T
Krausz, H
Ahle, G
Hager, B
Alfter, D
Schulze, T
Knapp, M
Maier, W
Rietschel, M
[J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (07) : 321 - 331
[8] CLINICAL PROFILES OF TARDIVE-DYSKINESIA
ITIL, TM
REISBERG, B
HUQUE, M
MEHTA, D
[J]. COMPREHENSIVE PSYCHIATRY, 1981, 22 (03) : 282 - 290
[9] Keeping Up with Clinical Advances: Opioid Use Disorder
Patel, Biren
Kosten, Thomas R.
[J]. CNS SPECTRUMS, 2019, 24 : 17 - 23
[10] TARDIVE-DYSKINESIA - PHARMACOLOGY AND CLINICAL IMPLICATIONS
GOETZ, CG
WEINER, WJ
NAUSIEDA, PA
KLAWANS, HL
[J]. CLINICAL NEUROPHARMACOLOGY, 1982, 5 (01) : 3 - 22

← 1 2 3 4 5 →